Holen Sie sich die Stockscreener-App
0.1925
1.00%
0.0019
Vorhandelsmarkt:
.20
0.0075
+3.90%
Schlusskurs vom Vortag:
$0.1906
Offen:
$0.1958
24-Stunden-Volumen:
754.36K
Relative Volume:
0.39
Marktkapitalisierung:
$12.60M
Einnahmen:
$1.56M
Nettoeinkommen (Verlust:
$-62.68M
KGV:
-0.1492
EPS:
-1.29
Netto-Cashflow:
$-64.35M
1W Leistung:
+1.74%
1M Leistung:
+6.94%
6M Leistung:
-31.25%
1J Leistung:
-96.30%
1-Tages-Spanne:
$0.191
$0.2011
1-Wochen-Bereich:
$0.1813
$0.2011
52-Wochen-Spanne:
$0.1625
$6.79
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Firmenname
Lyra Therapeutics Inc
Sektor
Branche
Telefon
617-373-4600
Adresse
480 ARSENAL WAY, WATERTOWN, MA
Vergleichen Sie LYRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
0.1925 | 12.60M | 1.56M | -62.68M | -64.35M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-07 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-05-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-05-06 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-26 | Eingeleitet | BTIG Research | Buy |
| 2020-05-26 | Eingeleitet | BofA/Merrill | Buy |
| 2020-05-26 | Eingeleitet | Jefferies | Buy |
| 2020-05-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Lyra Therapeutics Inc Aktie (LYRA) Neueste Nachrichten
Selling Your Galaxy Payroll Group Ltd (GLXG) Stock? Here’s What You Need To Know - Stocks Register
Data-Based Insights About Mister Car Wash Inc (MCW) - Stocks Register
There Is A Lot Of Upside Potential For Helius Medical Technologies Inc(NASDAQ: HSDT) - Stocks Register
New Outlook On Vestis Corp - Stocks Register
Cadiz Inc (CDZI): An Important Analyst Insights - Stocks Register
Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know - MSN
Chronic Rhinosinusitis Without Nasal Polyps Therapeutics - openPR
Revance Therapeutics jumps after Teoxane offers $3.60 a share - MSN
Cidara Therapeutics Announces Leadership Changes and Appointments - MSN
Are Investors Keen On Selling Holdings In Phoenix Motor Inc (NASDAQ: PEV)? - Stocks Register
State Street Corp Takes Position in Lotus Technology Inc. (NASDAQ:LOT) - Defense World
State Street Corp Has $126,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
Lyra Therapeutics reshuffles board, adjusts director classes - Investing.com
Lyra Therapeutics reshuffles board, adjusts director classes By Investing.com - Investing.com UK
Lyra Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lyra Therapeutics Inc’s (NASDAQ: LYRA) Stock Forecast: Increase To $0.5 In A Year - Stocks Register
Chronic Rhinosinusitis Without Nasal Polyps Therapeutics Market Size was ~USD 3,930 Million in the 7MM in 2023, estimated DelveInsight - Barchart
Incendia Therapeutics Names Healthcare Veteran Brad Smith as CFO, Brings $1B Financing Track Record - StockTitan
Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer - Business Wire
LYRA (Lyra Therapeutics) GF Score : 43/100 (As of Nov. 29, 2024) - GuruFocus.com
Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Price Target at $4.50 - Defense World
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital
William Blair Has Positive Forecast for LYRA FY2024 Earnings - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Lyra Therapeutics stock plunges to 52-week low of $0.21 By Investing.com - Investing.com South Africa
Lyra Therapeutics stock plunges to 52-week low of $0.21 - Investing.com India
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
Lyra Therapeutics Inc (LYRA) Q3 2024 Earnings: Net Loss of $11.9M, Misses EPS and Revenue Estimates - GuruFocus.com
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Lyra Therapeutics Reports Strong Safety Data, Cuts Q3 Losses by 24% as LYR-210 Advances | LYRA Stock News - StockTitan
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) PT at $4.50 - Defense World
Chronic Rhinosinusitis Market: Driving Rapid Growth with Top - openPR
Lyra Therapeutics Inc (NASDAQ: LYRA) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Lyra Therapeutics completes Phase 3 trial enrollment for CRS treatment By Investing.com - Investing.com Canada
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - The Manila Times
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Market Momentum: Lyra Therapeutics Inc (LYRA) Registers a 3.08 Increase, Closing at 0.24 - The Dwinnex
Lyra Therapeutics Inc (LYRA)’s stock price in review: A technical analysis - US Post News
Lyra Therapeutics Inc: Navigating a Turbulent Year, Up -96.61% from 52-Week Low - The InvestChronicle
Lyra Therapeutics stock plunges to 52-week low of $0.24 - Investing.com
Lyra Therapeutics stock plunges to 52-week low of $0.24 By Investing.com - Investing.com UK
What is the investor’s view on Lyra Therapeutics Inc (LYRA)? - US Post News
Kailera Therapeutics Launches with $400 Million Series A - GlobeNewswire
The time has not yet come to remove your chips from the table: Lyra Therapeutics Inc (LYRA) - SETE News
Where Do Analysts Think The Lyra Therapeutics Inc (NASDAQ: LYRA) Is Going - Stocks Register
Lyra Therapeutics Inc (LYRA) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Lyra Therapeutics to Present Study Results for LYR-210 and - GlobeNewswire
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - StockTitan
Finanzdaten der Lyra Therapeutics Inc-Aktie (LYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):